Creates the Prescription Drug Affordability Act. Defines terms. Creates the Prescription Drug Affordability Board and includes provisions regarding: purpose; members; alternate members; conflict of interest; terms; additional staff; salary; compensation and reimbursement; and meetings. Creates the Prescription Drug Affordability Stakeholder Council and includes provisions regarding: purpose; members; knowledge requirements; terms; and compensation. Provides the manner in which a conflict of interest shall be disclosed. Provides that gifts or donations of services or property that indicate a potential conflict of interest may not be accepted by any member of the Board, Board staff, or third-party contractor. Includes provisions on applicability. Provides that the Board shall identify specified prescription drug products and determine whether each prescription drug product should be subject to a cost review. Provides that if the Board finds that spending on a prescription drug product creates affordability challenges, the Board shall establish an upper payment limit that applies to all purchases and payor reimbursements. Includes provisions regarding remedies and an appeal process. Creates the Prescription Drug Affordability Fund. Provides that the Board shall submit a report to the General Assembly including specified information. Includes a provision on term expiration for Board and Council members. Provides that the Board shall conduct a study of the operation of the generic drug market that includes specified information on or before June 1, 2020. Makes conforming changes in the State Finance Act. Effective immediately.

Rep. Will Guzzardi – Mary E. Flowers – Karina Villa, Thaddeus Jones, Fred Crespo, Robert Rita, Jaime M. Andrade, Jr. and Terra Costa Howard

Creates the Wholesale Importation of Prescription Drugs Act. Requires the Department of Public Health to design an importation program where the State is the licensed wholesaler of imported drugs from licensed, regulated Canadian suppliers. Requires the program to address specified issues, including billing issues, cost savings issues, and safety and regulatory issues. Contains auditing and reporting requirements. Provides that the Department shall enlist the assistance of the Attorney General to identify the potential for anti-competitive behavior in industries that would be affected by an importation program. Requires the Department to submit a formal request to the Secretary of the United States Department of Health and Human Services for certification of the importation program. Requires the Department to have the program operational within 6 months after receiving the certification. Contains provisions concerning implementation requirements.

Rep. Anna Moeller – Natalie A. Manley

iBIO Position: Support

Amends the Medical Assistance Article of the Illinois Public Aid Code. Provides that the medical assistance program shall provide coverage for routine care costs that are incurred in the course of an approved clinical trial if the medical assistance program would provide coverage for the same routine care costs not incurred in a clinical trial. Defines “approved clinical trial” to mean a phase I, II, III, or IV clinical trial involving the prevention, detection, or treatment of cancer or any other life-threatening disease or condition. Defines “routine care cost” to mean the cost of medically necessary services related to the care method that is under evaluation in a clinical trial, including the cost of services related to the detection and treatment of any complications arising from the patient’s medical care and any complications related to participation in the clinical trial. Defines other terms.

Sen. Andy Manar – Melinda Bush – Celina Villanueva – Mattie Hunter – Iris Y. Martinez, Jennifer Bertino-Tarrant, Laura Ellman, Omar Aquino, Laura M. Murphy, Laura Fine, Patricia Van Pelt, Rachelle Crowe, Ram Villivalam, Jacqueline Y. Collins, Scott M. Bennett, Linda Holmes, Antonio Muñoz, Christopher Belt, Cristina Castro, Patrick J. Joyce, Heather A. Steans, Sara Feigenholtz and Kimberly A. Lightford

iBIO Position: Support

Amends the Medical Assistance Article of the Illinois Public Aid Code. Provides that the medical assistance program shall provide coverage for routine care costs that are incurred in the course of an approved clinical trial if the medical assistance program would provide coverage for the same routine care costs not incurred in a clinical trial. Defines “approved clinical trial” to mean a phase I, II, III, or IV clinical trial involving the prevention, detection, or treatment of cancer or any other life-threatening disease or condition. Defines “routine care cost” to mean the cost of medically necessary services related to the care method that is under evaluation in a clinical trial, including the cost of services related to the detection and treatment of any complications arising from the patient’s medical care and any complications related to participation in the clinical trial. Defines other terms.

Representative Camille Y. Lilly

Amends the Department of Commerce and Economic Opportunity Law of the Civil Administrative Code of Illinois. Establishes the Illinois Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Matching Funds Program to be administered by the Department of Commerce and Economic Opportunity. Provides that the Department of Commerce and Economic Opportunity may make grants to eligible businesses to match federal funds received by the business as an SBIR or STTR Phase I award and to encourage businesses to apply for Phase II awards up to a maximum of $50,000. Effective July 1, 2020.

Senator Elgie R. Sims, Jr.